Tehran University of Medical Sciences Journal of Pharmacoeconomics and Pharmaceutical Management 2383-4498 8 1/2 2022 06 18 38 41 Omid Barati Hospital Management Research Center, Iran University of Medical Sciences, Tehran, Iran. Amir Rezazadeh Department of Clinical Pharmacy, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran. Yaser Joyani Department of Health Economics, School of Health Management and Information, Iran University of Medical Sciences, Tehran, Iran. Nasim Afsari Manesh Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Alireza N. Farahmand Health Care Management, Shohadaye Yaftabad Hospital, Iran University of Medical Science, Tehran, Iran. Alireza Esmaeeli Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Zahra Sadat Mousavi Bafrouei Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2021 07 30 2022 06 19 Background: In public health emergencies, such as the COVID-19 pandemic, the work strategies of clinical pharmacists need to be modified according to the rapid spread of the disease, where information and resources are constantly changing. The aim of this study was to describe the role of clinical pharmacists in the COVID-19 pandemic by the implementation of clinical practice guidelines. Methods: This was a prospective study from September 2020 to March 2021 in a COVID-19 center hospital. A clinical pharmacist visited patients in the ICU and internal ward three times per week and delivered Comprehensive Medication Management (CMM) on a consultation paper in patient’s files. In October 2021, a consensus regarding the improvement of the rational use of COVID-19 medications and their costs was developed. The high-cost medications were selected based on the hospital information system to evaluate direct medical costs from the provider’s perspective. Results: During six months, in addition to pharmacotherapy consultation for 193 patients, pharmacotherapy evaluation was done 903 times for COVID-19 patients and their medication was also assessed. After implementation of the updated COVID-19 protocol in the hospital, the use of main drugs reduced by 8.950.328.786 IRR equivalent to 21,317 USD based on reference currency within two months. Conclusion: The participation of a clinical pharmacist in a COVID-19 center by the implementation of pharmacotherapy guidelines and comprehensive medication management may lead to cost reduction and improved drug safety. https://jppm.tums.ac.ir/index.php/jppm/article/view/171 https://jppm.tums.ac.ir/index.php/jppm/article/download/171/83